Drug intelligence / Profile preview

Dolasynthen DAR-2 ADC

Development stage: Discontinued
Lead developer: Mersana Therapeutics
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Dolasynthen DAR-2 ADC refers to a class of antibody-drug conjugates (ADCs) developed using Mersana Therapeutics' proprietary Dolasynthen platform, characterized by a drug-to-antibody ratio (DAR) of 2. The Dolasynthen platform utilizes a fully synthetic, biodegradable scaffold to enable precise, site-specific conjugation of auristatin-based payloads (such as auristatin hydroxypropylamide, or AF-HPA) to targeting antibodies. In preclinical studies, Dolasynthen DAR-2 ADCs (such as those targeting B7-H4 or HER2) have been evaluated as comparators alongside higher DAR variants (e.g., DAR-6 and DAR-12) to optimize the therapeutic index, pharmacokinetics, and efficacy of clinical candidates like XMT-1660.

Other names: Dolasynthen DAR 2 ADCDolasynthen DAR-2

Targets

VTCN1 (V-set domain containing T cell activation inhibitor 1)TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on Dolasynthen DAR-2 ADC.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dolasynthen DAR-2 ADC.

Explore the full profile